Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Chronic Myeloid Leukaemia

Role of pretransplant interferon-α(IFN) treatment in the outcome of stem cell transplantation (SCT) from related donors in chronic myelogenous leukemia (CML): results from three Turkish transplant centers

Bone Marrow Transplantation volume 31, pages 897–904 (2003)Cite this article

Summary:

Since transplantation cannot be performed immediately after the diagnosis of chronic myelogenous leukemia (CML), interferon treatment is usually required. This study aims to analyze the effects of interferon-α (IFN) treatment on allogeneic stem cell transplantation (SCT) outcome. A total of 106 patients aged 16–47 years and transplanted from HLA-identical sibling donors for CML in chronic phase (CP) were evaluated. In all, 48 had received IFN-α for a median duration of 5 months (1–18 months) until a median of 1 month prior to transplantation. Of the patients, 50 have received bone marrow transplant (BMT) whereas 56 have received peripheral blood stem cells (PBSCT) between 1991 and 1999 in three major transplant centers in Turkey. Patient characteristics in both groups were similar. More hematological responders were present in the IFN(+) patients (P=0.0001). No difference was found in engraftment kinetics. The incidences of acute or chronic graft-versus-host disease (GVHD), relapse and graft failure were similar in all patients regardless of stem cell source. Overall survival (OS) and disease-free survival (DFS) at 2 years were similar for both IFN(+) or (−) patients following SCT. With multivariate analysis, pretransplant IFN-α use, stem cell source, transplant year and CD34+ cell content were not found to be risk factors for OS. In conclusion, prior IFN exposure did not impair BMT or PBSCT outcome.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 3
Figure 2
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Sawyers CL . Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330–1340.

    Article  CAS  Google Scholar 

  2. Chronic Myeloid Leukemia Trialists' Collaborative Group. Hydroxyurea versus busulphan for chronic myeloid leukemia: an individual patient data meta-analysis of three randomized trials. Br Med J 2000; 110: 573–576.

  3. Speck B, Bortin MM, Champlin R et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia. Lancet 1984; 1: 665–668.

    Article  CAS  Google Scholar 

  4. Thomas ED, Clift RA, Fefer A et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986; 104: 155–163.

    Article  CAS  Google Scholar 

  5. Goldman JM, Apperley JF, Jones L et al. Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 1993; 314: 202–207.

    Article  Google Scholar 

  6. Appelbaum FR, Clift R, Radich J et al. Bone marrow transplantation for chronic myelogenous leukemia. Semin Oncol 1995; 22: 405–411.

    CAS  Google Scholar 

  7. Barrett AJ, Malkovska V . Graft-versus-leukemia understanding and using the alloimmune response to treat haematological malignancy. Br J Haematol 1999; 93: 754–761.

    Article  Google Scholar 

  8. Talpaz M, Kantarjian H, Kurzrock R et al. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med 1991; 114: 532–538.

    Article  CAS  Google Scholar 

  9. Talpaz M, Kantarjian HM, McCredie K et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha in chronic myelogenous leukemia. N Engl J Med 1986; 314: 1065–1069.

    Article  CAS  Google Scholar 

  10. Ozer H, George SL, Schiffer CA et al. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival. Cancer and Leukemia Group B study 8583. Blood 1993; 82: 2975–2984.

    CAS  Google Scholar 

  11. Kantarjian HM, Smith TL, O'Brien S et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon alpha therapy. Ann Int Med 1995; 122: 254–261.

    Article  CAS  Google Scholar 

  12. Italian Cooperative Study on Chronic Myeloid Leukemia. Interferon alpha-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330: 820–825.

  13. Hehlmann R, Heimpel H, Hasford J et al. The German CML Study Group: randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 1994; 84: 4064–4077.

    CAS  Google Scholar 

  14. Lindauer M, Domkin D, Döhner H et al. Efficacy and toxicity of IFN-a2b combined with cytarabine in chronic myeloid leukemia. Br J Haematol 1999; 106: 1013–1019.

    Article  CAS  Google Scholar 

  15. Kloke O, Niederle N, Qiu JY et al. Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myeloid leukemia. Br J Haematol 1993; 83: 399–403.

    Article  CAS  Google Scholar 

  16. Yee K, Anglin P, Keating A . Molecular approaches to the detection and monitoring of chronic myeloid leukemia: theory and practice. Blood Rev 1999; 13: 105–126.

    Article  CAS  Google Scholar 

  17. Goldman JM, Druker BJ . Chronic myeloid leukemia: current treatment options. Blood 2001; 98: 2039–2042.

    Article  CAS  Google Scholar 

  18. Hehlmann R, Hochhaus A, Kolb HJ et al. Interferon-α before allogeneic bone marrow transplantation in chronic myelo-genous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. Blood 1999; 94: 3668–3677.

    CAS  PubMed  Google Scholar 

  19. Giralt S, Szydlo JM, Goldman JM et al. Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myeloid leukemia: an analysis from the International Bone Marrow Transplantation Registry. Blood 2000; 95: 410–415.

    CAS  Google Scholar 

  20. Lee SJ, Klein JP, Anasetti C et al. The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase. Blood 2001; 98: 3205–3211.

    Article  CAS  Google Scholar 

  21. Pigneux A, Tanguy ML, Michalet M et al. Prior treatment with alpha interferon does not adversely affect the outcome of allogeneic transplantation for chronic myeloid leukemia. Br J Haematol 2002; 116: 193–201.

    Article  CAS  Google Scholar 

  22. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus host disease in human recipients of marrow from HLA matched sibling donors. Transplantation 1974; 18: 295–304.

    Article  CAS  Google Scholar 

  23. Thomas ED, Storb R, Clift RA et al. Bone marrow transplantation. N Engl Med 1975; 292: 895.

    Article  CAS  Google Scholar 

  24. Hasford J, Pfirrmann M, Hehlmann R et al. A new prognostic score for the survival of patients with chronic myeloid leukemia treated with interferon alpha (Internet: http://www.pharmacoepi.de/cmlscore.html for an online calculator). J Natl Cancer Inst 1998; 90: 850–858.

    Article  CAS  Google Scholar 

  25. Baron S, Trying SK, Fleichmann Jr WR et al. The interferons: mechanisms of action and clinical applications. JAMA 1991; 266: 1375–1383.

    Article  CAS  Google Scholar 

  26. Giralt SA, Kantarjian HM, Talpaz M et al. Effect of prior interferon Alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol 1993; 11: 1055–1061.

    Article  CAS  Google Scholar 

  27. Morton AJ, Gooley T, Hansen JA et al. Association between pretransplant interferon-α and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood 1998; 92: 394–401.

    CAS  PubMed  Google Scholar 

  28. Beelen DW, Graeven U, Elmaagacli AH et al. Prolonged administration of interferon-α in patients with chronic myelogeneous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 1995; 85: 2981–2990.

    CAS  PubMed  Google Scholar 

  29. Zuffa E, Bandini G, Bonini A et al. Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia. Haematologica 1998; 83: 231–236.

    CAS  PubMed  Google Scholar 

  30. Passweg J, Walker K, Sobocinski B et al. Validation of the EBMT risk score for recipients of allogeneic hematopoetic stem cell transplantation for chronic myeloid leukemia (CML). Bone Marrow Transplant 2002; 29 (Suppl 2): S33.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. BMT Unit, Ankara University School of Medicine, Ankara, Turkey

    M Beksac, H Çelebi, P Topcuoglu, O Arslan, M Ozcan, G Gurman, O İlhan & H Akan

  2. BMT Unit, Istanbul University School of Medicine, Istanbul

    D Sargín & S Kalayoglu-Besisik

  3. BMT Unit, Gulhane Military Medical Academy, Ankara, Turkey

    A Yalcin & C Beyan

Authors
  1. M Beksac
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H Çelebi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D Sargín
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Yalcin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P Topcuoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Kalayoglu-Besisik
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Beyan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. O Arslan
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M Ozcan
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G Gurman
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. O İlhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. H Akan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Beksac, M., Çelebi, H., Sargín, D. et al. Role of pretransplant interferon-α(IFN) treatment in the outcome of stem cell transplantation (SCT) from related donors in chronic myelogenous leukemia (CML): results from three Turkish transplant centers. Bone Marrow Transplant 31, 897–904 (2003). https://doi.org/10.1038/sj.bmt.1703930

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703930

Keywords

Search

Advanced search

Quick links